直接抗病毒药物根除丙肝降低静脉曲张出血风险
结果显示,获得持续病毒学应答(SVR)与静脉曲张出血发生率显著降低独立相关,在治疗前有或无肝硬化患者中均成立。
要点
- DAA治疗获得SVR者静脉曲张出血发生率显著低于未获得SVR者(0.46 vs 1.26/100人年)。
- 治疗前有肝硬化者SVR后出血风险仍降低(AHR 0.73),无肝硬化者降低更明显(AHR 0.33)。
- 治疗前已有非出血或出血静脉曲张者,SVR后出血风险数值上更低但校正后差异无统计学意义。
核心结论
- DAA诱导的SVR与治疗后有或无肝硬化患者长期随访中静脉曲张出血风险降低独立相关。
- 这些发现展示了DAA治疗在真实世界中的重要获益。
研究设计与样本
- 研究纳入美国退伍军人医疗系统2013至2015年启动DAA-only抗病毒治疗的丙肝患者,随访至2019年1月1日。
- 采用多因素Cox比例风险回归评估SVR与静脉曲张出血的关联,并校正潜在混杂因素。
主要发现
- 549例(1.6%)患者在治疗后发生静脉曲张出血。
- 全部患者中,SVR组 vs 无SVR组静脉曲张出血发生率为0.46 vs 1.26/100人年,AHR 0.66(95%CI 0.52-0.83)。
- 治疗前有肝硬化者中,SVR组 vs 无SVR组发生率为1.55 vs 2.96/100人年,AHR 0.73(95%CI 0.57-0.93)。
- 治疗前无肝硬化者中,SVR组 vs 无SVR组发生率为0.07 vs 0.29/100人年,AHR 0.33(95%CI 0.17-0.65)。
- 治疗前有非出血静脉曲张者SVR组 vs 无SVR组发生率为3.5 vs 4.9/100人年,有出血静脉曲张者为12.9 vs 16.4/100人年,但校正分析差异无统计学意义。
临床怎么用
- 对丙肝患者应积极使用DAA治疗以实现SVR,以降低长期静脉曲张出血风险。
- 治疗前无肝硬化者获得SVR后静脉曲张出血风险降低更为显著。
- 治疗前已有静脉曲张者仍需关注出血风险,SVR的额外降低作用在校正分析中未达统计学显著。
局限性
- 静脉曲张出血通过诊断代码定义,可能存在误分类。
- 研究观察性设计,尽管多因素校正,仍可能存在残余混杂。
- 研究人群为美国退伍军人,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The real-world, long-term benefits of sustained virologic response (SVR) on the risk of variceal bleeding remain unclear. AIM: To assess the association between DAA-induced SVR and post-treatment variceal bleeding METHODS: We identified patients who initiated DAA-only anti-viral treatments in the United States Veterans Affairs healthcare system from 2013 to 2015. We followed patients until 1 January 2019 for the development of gastro-oesophageal variceal bleeding defined by diagnostic codes. We used multivariable Cox proportional hazards regression to assess the association between SVR and development of variceal bleeding, adjusting for potential confounders. RESULTS: Among 33 582 DAA-treated patients, 549 (1.6%) developed variceal bleeding after treatment (mean follow-up 3.1 years). Compared to no SVR, SVR was associated with a significantly lower incidence of variceal bleeding among all patients (0.46 vs 1.26 per 100 patient-years, adjusted hazard ratio [AHR] 0.66, 95% CI 0.52-0.83), among patients with pre-treatment cirrhosis (1.55 vs 2.96 per 100 patient-years, AHR 0.73, 95% CI 0.57-0.93) and among patients without pre-treatment cirrhosis (0.07 vs 0.29 per 100 patient-years, AHR 0.33, 95% CI 0.17-0.65). The risk of variceal bleeding after treatment was lower in those who achieved SVR vs no SVR among patients who had non-bleeding varices (3.5 vs 4.9 per 100 patient-years) or bleeding varices (12.9 vs 16.4 per 100 patient-years) diagnosed before treatment, but these differences were not statistically significant in adjusted analyses. CONCLUSION: DAA-induced SVR is independently associated with a lower risk of variceal bleeding during long-term follow-up in patients with and without pre-treatment cirrhosis. These findings demonstrate an important real-world benefit of DAA treatment.
引用
- Moon AM, Green PK, Rockey DC, et al. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. Aliment Pharmacol Ther. 2019. PMID: 31773763. doi:10.1111/apt.15586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。